HEART-3: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=175 | Not yet recruiting | Sponsor: Verve Therapeutics, Inc.
New P2 trial • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOB
|